Table 1.

Summarization of Anti-VEGF drugs

Drug name	Mechanism	Indications	Status	References
Bevacizumab (Avastin)	A humanized anti-VEGF antibody	Metastatic colorectal cancer, non-small cell lung cancer, recurrent glioblastoma multiforme and metastatic breast cancer in combination with chemotherapy Renal cell carcinoma in combination with interferon alpha	FDA approved	(114, 115) 116) (117)
Pegaptanib	An anti-VEGF RNA aptamer	All types of neovascular age-related macular degeneration (AMD)	FDA approved	(128)
VEGF Trap	A soluble VEGF receptor	Refractory solid tumors or non-Hodgkin's lymphoma	Phase I	(138)
Sunitinib malate	A inhibitor of VEGFRs, FLT3, c-KIT, and PDGFRs	Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate Advanced renal cell carcinoma	FDA approved	(143)
Sorafenib	A inhibitor of VEGFRs, PDGFRs, FLT3, RAF-1, and BRAF	Metastatic renal cell carcinoma and hepatocellular carcinoma	FDA approved	(145)
Pazopanib	A inhibitor of VEGFRs, PDGFRs, and c-kit	Metastatic RCC Recurrent glioblastoma	Phase II	(148) (149)
Ramucirumab	A fully humanized MAb targeting to the extracellular VEGF-binding domain of VEGFR-2	Advanced solid malignancies	Phase I	(153)